Impact of preexisting type 2 diabetes mellitus and antidiabetic drugs on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer
•Among women with breast cancer, those with type 2 diabetes had higher mortality hazard than nondiabetics.•Women prescribed sulfonylurea or insulin had an elevated mortality hazard compared to women prescribed metformin.•Among women 50 years of age and older with breast cancer, those with type 2 dia...
Gespeichert in:
| Veröffentlicht in: | Cancer epidemiology 2020-06, Vol.66, p.101710-101710, Article 101710 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 101710 |
|---|---|
| container_issue | |
| container_start_page | 101710 |
| container_title | Cancer epidemiology |
| container_volume | 66 |
| creator | Lawrence, Wayne R. Hosler, Akiko S. Gates Kuliszewski, Margaret Leinung, Matthew C. Zhang, Xiuling Schymura, Maria J. Boscoe, Francis P. |
| description | •Among women with breast cancer, those with type 2 diabetes had higher mortality hazard than nondiabetics.•Women prescribed sulfonylurea or insulin had an elevated mortality hazard compared to women prescribed metformin.•Among women 50 years of age and older with breast cancer, those with type 2 diabetes had a 47% higher mortality hazard.
We investigated the influence preexisting type 2 diabetes mellitus (T2DM) and antidiabetic drugs have on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer.
9221 women aged |
| doi_str_mv | 10.1016/j.canep.2020.101710 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9920233</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1877782120300448</els_id><sourcerecordid>2425648294</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-d7175cce69af950b5bb6cad55a44f757c07fe233dffea52af1bc5317b03e9a7a3</originalsourceid><addsrcrecordid>eNp9UsuO1DAQjBCIXRa-AAlZ4sIlgx9JnBxAQiseKy3iAhI3q2N3Zj1K7GA7C_NJ_CWeyTICDhwsP7q62l1dRfGU0Q2jrHm522hwOG845ccXyei94py1UpayFV_vn86cnRWPYtxR2jSM1Q-LM8F5JTltz4ufV9MMOhE_kDkg_rAxWbclaT8j4cRY6DFhJBOOo01LJOBMXsmuEauJCcs2Eu8IjGOpYYl4xBxPZZxR2yGjJh8SZIY9gcln_o9orAZrSuviEtCQ735Cd6i3dT4e7jbdkD4gxJS5nMbwuHgwwBjxyd1-UXx59_bz5Yfy-tP7q8s316WuWplKI5mstcamg6GraV_3faPB1DVU1SBrqakckAthhgGh5jCwXteCyZ4K7ECCuCher7zz0k9oNLoUYFRzsBOEvfJg1d8RZ2_U1t-qrsuTECITvLgjCP7bgjGpyUadBczT8ktUXLQNb5usf4Y-_we680twuT3FK143Vcu7KqPEitLBxxhwOH2GUXWwgtqpoxXUwQpqtULOevZnH6ec37PPgFcrALOatxaDitpiltrYgDop4-1_C_wCUuHLJg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425648294</pqid></control><display><type>article</type><title>Impact of preexisting type 2 diabetes mellitus and antidiabetic drugs on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Lawrence, Wayne R. ; Hosler, Akiko S. ; Gates Kuliszewski, Margaret ; Leinung, Matthew C. ; Zhang, Xiuling ; Schymura, Maria J. ; Boscoe, Francis P.</creator><creatorcontrib>Lawrence, Wayne R. ; Hosler, Akiko S. ; Gates Kuliszewski, Margaret ; Leinung, Matthew C. ; Zhang, Xiuling ; Schymura, Maria J. ; Boscoe, Francis P.</creatorcontrib><description>•Among women with breast cancer, those with type 2 diabetes had higher mortality hazard than nondiabetics.•Women prescribed sulfonylurea or insulin had an elevated mortality hazard compared to women prescribed metformin.•Among women 50 years of age and older with breast cancer, those with type 2 diabetes had a 47% higher mortality hazard.
We investigated the influence preexisting type 2 diabetes mellitus (T2DM) and antidiabetic drugs have on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer.
9221 women aged <64 years diagnosed with breast cancer and reported to the New York State (NYS) Cancer Registry from 2004 to 2016 were linked with Medicaid claims. Preexisting T2DM was determined by three diagnosis claims for T2DM with at least one claim prior to breast cancer diagnosis and a prescription claim for an antidiabetic drug within three months following breast cancer diagnosis. Estimated menopausal status was determined by age (premenopausal age <50; postmenopausal age ≥50). Hazard ratios (HR) and 95 % confidence intervals (95 %CI) were calculated with Cox proportional hazards regression, adjusting for confounders.
Women with preexisting T2DM had greater all-cause (HR = 1.40; 95 %CI 1.21, 1.63), cancer-specific (HR = 1.24; 95 %CI 1.04, 1.47), and cardiovascular-specific (HR = 2.46; 95 %CI 1.54, 3.90) mortality hazard compared to nondiabetic women. In subgroup analyses, the association between T2DM and all-cause mortality was found among non-Hispanic White (HR 1.78 95 %CI 1.38, 2.30) and postmenopausal (HR = 1.47; 95 %CI 1.23, 1.77) women, but not among other race/ethnicity groups or premenopausal women. Additionally, compared to women prescribed metformin, all-cause mortality hazard was elevated among women prescribed sulfonylurea (HR = 1.44; 95 %CI 1.06, 1.94) or insulin (HR = 1.54; 95 %CI 1.12, 2.11).
Among Medicaid-insured women with breast cancer, those with preexisting T2DM have an increased mortality hazard, especially when prescribed sulfonylurea or insulin. Further research is warranted to determine the role antidiabetic drugs have on survival among women with breast cancer.</description><identifier>ISSN: 1877-7821</identifier><identifier>EISSN: 1877-783X</identifier><identifier>DOI: 10.1016/j.canep.2020.101710</identifier><identifier>PMID: 32247208</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Age ; Antidiabetics ; Breast cancer ; Breast Neoplasms - complications ; Breast Neoplasms - mortality ; Cancer ; Cancer registry ; Cancer therapies ; Cardiovascular ; Cardiovascular disease ; Cause of Death - trends ; Chronology ; Confidence intervals ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - epidemiology ; Diagnosis ; Epidemiology ; Female ; Glucose-lowering drugs ; Government programs ; Health hazards ; Health risk assessment ; Humans ; Hypoglycemic Agents - pharmacology ; Hypoglycemic Agents - therapeutic use ; Insulin ; Medicaid ; Medicaid - standards ; Menopause ; Metformin ; Middle Aged ; Minority & ethnic groups ; Mortality ; Post-menopause ; Statistical analysis ; Subgroups ; Sulfonylurea ; United States</subject><ispartof>Cancer epidemiology, 2020-06, Vol.66, p.101710-101710, Article 101710</ispartof><rights>2020</rights><rights>Published by Elsevier Ltd.</rights><rights>Copyright Elsevier Limited Jun 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-d7175cce69af950b5bb6cad55a44f757c07fe233dffea52af1bc5317b03e9a7a3</citedby><cites>FETCH-LOGICAL-c487t-d7175cce69af950b5bb6cad55a44f757c07fe233dffea52af1bc5317b03e9a7a3</cites><orcidid>0000-0003-0642-1060 ; 0000-0002-2992-5897</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1877782120300448$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32247208$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lawrence, Wayne R.</creatorcontrib><creatorcontrib>Hosler, Akiko S.</creatorcontrib><creatorcontrib>Gates Kuliszewski, Margaret</creatorcontrib><creatorcontrib>Leinung, Matthew C.</creatorcontrib><creatorcontrib>Zhang, Xiuling</creatorcontrib><creatorcontrib>Schymura, Maria J.</creatorcontrib><creatorcontrib>Boscoe, Francis P.</creatorcontrib><title>Impact of preexisting type 2 diabetes mellitus and antidiabetic drugs on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer</title><title>Cancer epidemiology</title><addtitle>Cancer Epidemiol</addtitle><description>•Among women with breast cancer, those with type 2 diabetes had higher mortality hazard than nondiabetics.•Women prescribed sulfonylurea or insulin had an elevated mortality hazard compared to women prescribed metformin.•Among women 50 years of age and older with breast cancer, those with type 2 diabetes had a 47% higher mortality hazard.
We investigated the influence preexisting type 2 diabetes mellitus (T2DM) and antidiabetic drugs have on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer.
9221 women aged <64 years diagnosed with breast cancer and reported to the New York State (NYS) Cancer Registry from 2004 to 2016 were linked with Medicaid claims. Preexisting T2DM was determined by three diagnosis claims for T2DM with at least one claim prior to breast cancer diagnosis and a prescription claim for an antidiabetic drug within three months following breast cancer diagnosis. Estimated menopausal status was determined by age (premenopausal age <50; postmenopausal age ≥50). Hazard ratios (HR) and 95 % confidence intervals (95 %CI) were calculated with Cox proportional hazards regression, adjusting for confounders.
Women with preexisting T2DM had greater all-cause (HR = 1.40; 95 %CI 1.21, 1.63), cancer-specific (HR = 1.24; 95 %CI 1.04, 1.47), and cardiovascular-specific (HR = 2.46; 95 %CI 1.54, 3.90) mortality hazard compared to nondiabetic women. In subgroup analyses, the association between T2DM and all-cause mortality was found among non-Hispanic White (HR 1.78 95 %CI 1.38, 2.30) and postmenopausal (HR = 1.47; 95 %CI 1.23, 1.77) women, but not among other race/ethnicity groups or premenopausal women. Additionally, compared to women prescribed metformin, all-cause mortality hazard was elevated among women prescribed sulfonylurea (HR = 1.44; 95 %CI 1.06, 1.94) or insulin (HR = 1.54; 95 %CI 1.12, 2.11).
Among Medicaid-insured women with breast cancer, those with preexisting T2DM have an increased mortality hazard, especially when prescribed sulfonylurea or insulin. Further research is warranted to determine the role antidiabetic drugs have on survival among women with breast cancer.</description><subject>Age</subject><subject>Antidiabetics</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - complications</subject><subject>Breast Neoplasms - mortality</subject><subject>Cancer</subject><subject>Cancer registry</subject><subject>Cancer therapies</subject><subject>Cardiovascular</subject><subject>Cardiovascular disease</subject><subject>Cause of Death - trends</subject><subject>Chronology</subject><subject>Confidence intervals</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - epidemiology</subject><subject>Diagnosis</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Glucose-lowering drugs</subject><subject>Government programs</subject><subject>Health hazards</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin</subject><subject>Medicaid</subject><subject>Medicaid - standards</subject><subject>Menopause</subject><subject>Metformin</subject><subject>Middle Aged</subject><subject>Minority & ethnic groups</subject><subject>Mortality</subject><subject>Post-menopause</subject><subject>Statistical analysis</subject><subject>Subgroups</subject><subject>Sulfonylurea</subject><subject>United States</subject><issn>1877-7821</issn><issn>1877-783X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9UsuO1DAQjBCIXRa-AAlZ4sIlgx9JnBxAQiseKy3iAhI3q2N3Zj1K7GA7C_NJ_CWeyTICDhwsP7q62l1dRfGU0Q2jrHm522hwOG845ccXyei94py1UpayFV_vn86cnRWPYtxR2jSM1Q-LM8F5JTltz4ufV9MMOhE_kDkg_rAxWbclaT8j4cRY6DFhJBOOo01LJOBMXsmuEauJCcs2Eu8IjGOpYYl4xBxPZZxR2yGjJh8SZIY9gcln_o9orAZrSuviEtCQ735Cd6i3dT4e7jbdkD4gxJS5nMbwuHgwwBjxyd1-UXx59_bz5Yfy-tP7q8s316WuWplKI5mstcamg6GraV_3faPB1DVU1SBrqakckAthhgGh5jCwXteCyZ4K7ECCuCher7zz0k9oNLoUYFRzsBOEvfJg1d8RZ2_U1t-qrsuTECITvLgjCP7bgjGpyUadBczT8ktUXLQNb5usf4Y-_we680twuT3FK143Vcu7KqPEitLBxxhwOH2GUXWwgtqpoxXUwQpqtULOevZnH6ec37PPgFcrALOatxaDitpiltrYgDop4-1_C_wCUuHLJg</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Lawrence, Wayne R.</creator><creator>Hosler, Akiko S.</creator><creator>Gates Kuliszewski, Margaret</creator><creator>Leinung, Matthew C.</creator><creator>Zhang, Xiuling</creator><creator>Schymura, Maria J.</creator><creator>Boscoe, Francis P.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0642-1060</orcidid><orcidid>https://orcid.org/0000-0002-2992-5897</orcidid></search><sort><creationdate>20200601</creationdate><title>Impact of preexisting type 2 diabetes mellitus and antidiabetic drugs on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer</title><author>Lawrence, Wayne R. ; Hosler, Akiko S. ; Gates Kuliszewski, Margaret ; Leinung, Matthew C. ; Zhang, Xiuling ; Schymura, Maria J. ; Boscoe, Francis P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-d7175cce69af950b5bb6cad55a44f757c07fe233dffea52af1bc5317b03e9a7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Age</topic><topic>Antidiabetics</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - complications</topic><topic>Breast Neoplasms - mortality</topic><topic>Cancer</topic><topic>Cancer registry</topic><topic>Cancer therapies</topic><topic>Cardiovascular</topic><topic>Cardiovascular disease</topic><topic>Cause of Death - trends</topic><topic>Chronology</topic><topic>Confidence intervals</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - epidemiology</topic><topic>Diagnosis</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Glucose-lowering drugs</topic><topic>Government programs</topic><topic>Health hazards</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin</topic><topic>Medicaid</topic><topic>Medicaid - standards</topic><topic>Menopause</topic><topic>Metformin</topic><topic>Middle Aged</topic><topic>Minority & ethnic groups</topic><topic>Mortality</topic><topic>Post-menopause</topic><topic>Statistical analysis</topic><topic>Subgroups</topic><topic>Sulfonylurea</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lawrence, Wayne R.</creatorcontrib><creatorcontrib>Hosler, Akiko S.</creatorcontrib><creatorcontrib>Gates Kuliszewski, Margaret</creatorcontrib><creatorcontrib>Leinung, Matthew C.</creatorcontrib><creatorcontrib>Zhang, Xiuling</creatorcontrib><creatorcontrib>Schymura, Maria J.</creatorcontrib><creatorcontrib>Boscoe, Francis P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lawrence, Wayne R.</au><au>Hosler, Akiko S.</au><au>Gates Kuliszewski, Margaret</au><au>Leinung, Matthew C.</au><au>Zhang, Xiuling</au><au>Schymura, Maria J.</au><au>Boscoe, Francis P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of preexisting type 2 diabetes mellitus and antidiabetic drugs on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer</atitle><jtitle>Cancer epidemiology</jtitle><addtitle>Cancer Epidemiol</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>66</volume><spage>101710</spage><epage>101710</epage><pages>101710-101710</pages><artnum>101710</artnum><issn>1877-7821</issn><eissn>1877-783X</eissn><abstract>•Among women with breast cancer, those with type 2 diabetes had higher mortality hazard than nondiabetics.•Women prescribed sulfonylurea or insulin had an elevated mortality hazard compared to women prescribed metformin.•Among women 50 years of age and older with breast cancer, those with type 2 diabetes had a 47% higher mortality hazard.
We investigated the influence preexisting type 2 diabetes mellitus (T2DM) and antidiabetic drugs have on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer.
9221 women aged <64 years diagnosed with breast cancer and reported to the New York State (NYS) Cancer Registry from 2004 to 2016 were linked with Medicaid claims. Preexisting T2DM was determined by three diagnosis claims for T2DM with at least one claim prior to breast cancer diagnosis and a prescription claim for an antidiabetic drug within three months following breast cancer diagnosis. Estimated menopausal status was determined by age (premenopausal age <50; postmenopausal age ≥50). Hazard ratios (HR) and 95 % confidence intervals (95 %CI) were calculated with Cox proportional hazards regression, adjusting for confounders.
Women with preexisting T2DM had greater all-cause (HR = 1.40; 95 %CI 1.21, 1.63), cancer-specific (HR = 1.24; 95 %CI 1.04, 1.47), and cardiovascular-specific (HR = 2.46; 95 %CI 1.54, 3.90) mortality hazard compared to nondiabetic women. In subgroup analyses, the association between T2DM and all-cause mortality was found among non-Hispanic White (HR 1.78 95 %CI 1.38, 2.30) and postmenopausal (HR = 1.47; 95 %CI 1.23, 1.77) women, but not among other race/ethnicity groups or premenopausal women. Additionally, compared to women prescribed metformin, all-cause mortality hazard was elevated among women prescribed sulfonylurea (HR = 1.44; 95 %CI 1.06, 1.94) or insulin (HR = 1.54; 95 %CI 1.12, 2.11).
Among Medicaid-insured women with breast cancer, those with preexisting T2DM have an increased mortality hazard, especially when prescribed sulfonylurea or insulin. Further research is warranted to determine the role antidiabetic drugs have on survival among women with breast cancer.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>32247208</pmid><doi>10.1016/j.canep.2020.101710</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-0642-1060</orcidid><orcidid>https://orcid.org/0000-0002-2992-5897</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1877-7821 |
| ispartof | Cancer epidemiology, 2020-06, Vol.66, p.101710-101710, Article 101710 |
| issn | 1877-7821 1877-783X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9920233 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Age Antidiabetics Breast cancer Breast Neoplasms - complications Breast Neoplasms - mortality Cancer Cancer registry Cancer therapies Cardiovascular Cardiovascular disease Cause of Death - trends Chronology Confidence intervals Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology Diagnosis Epidemiology Female Glucose-lowering drugs Government programs Health hazards Health risk assessment Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Insulin Medicaid Medicaid - standards Menopause Metformin Middle Aged Minority & ethnic groups Mortality Post-menopause Statistical analysis Subgroups Sulfonylurea United States |
| title | Impact of preexisting type 2 diabetes mellitus and antidiabetic drugs on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T06%3A16%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20preexisting%20type%202%20diabetes%20mellitus%20and%20antidiabetic%20drugs%20on%20all-cause%20and%20cause-specific%20mortality%20among%20Medicaid-insured%20women%20diagnosed%20with%20breast%20cancer&rft.jtitle=Cancer%20epidemiology&rft.au=Lawrence,%20Wayne%20R.&rft.date=2020-06-01&rft.volume=66&rft.spage=101710&rft.epage=101710&rft.pages=101710-101710&rft.artnum=101710&rft.issn=1877-7821&rft.eissn=1877-783X&rft_id=info:doi/10.1016/j.canep.2020.101710&rft_dat=%3Cproquest_pubme%3E2425648294%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2425648294&rft_id=info:pmid/32247208&rft_els_id=S1877782120300448&rfr_iscdi=true |